Pharmaceutical company Enesi Pharma reported on Monday the launch of a research and development collaboration for novel needle-free solid-dose vaccine for emergent threat pathogens with Public Health England (PHE), an executive agency of the UK Government's Department of Health and Social Care.
PHE will reportedly develop and evaluate a novel solid-dose formulation of a number of its proprietary vaccine candidates including Anthrax recombinant Protective Antigen (rPA) and Crimean-Congo Haemorrhagic Fever (CCHF) for delivery using Enesi Pharma's ImplaVax needle-free technology.
In conjunction, the pre-clinical testing of a range of ImplaVax enabled vaccines in animal models has evidenced regimen sparing and a reduced time to achieve threshold immunity against comparative conventional liquid vaccines administered using a needle and syringe.
The ImplaVax's enabled vaccines saves time and money, allowing more patients to be vaccinated more quickly from a fixed available production volume, potentially expanding coverage, preparedness and emergency response. The current vaccination schedules of many vaccines require multiple doses.
An ImplaVax-enabled vaccine can enhance vaccination programmes for military and other at-risk personnel, provide a rapidly deployable therapeutic option for individuals who have been exposed to the target infectious disease, benefit from extended thermal stability, reduce the end to end cold chain logistical challenges, cost as well as greatly assist in optimising the cost effectiveness of the national strategic stockpile.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer